This year, Zentiva will be present in Hall 3.0 – Finished Dosage Forms, at Stand 3.0G20, with a dedicated booth designed to facilitate dialogue and showcase our commitment to sustainability and innovation.Our presence at CPHI Frankfurt underscores Zentiva’s role as a trusted and reliable partner in the European pharmaceutical landscape. Our expanding portfolio reflects a commitment to advancing healthcare through biosimilars, value-added medicines, and tailored solutions that support the health and wellbeing of all generations.Visitors to our booth will have the opportunity to engage with experts from Zentiva’s B2B, Business Development, Product Supply, Product Launch, Procurement, Corporate Affairs, and Sustainability. Together, we will explore new opportunities for collaboration, discuss market trends, and share insights into our strategic initiatives. Our team will also be available to present our capabilities in commercialization, our track record of successful launches, and our vision for future growth in the biosimilars segment.  How to connectTo stay updated on our presence at CPHI Frankfurt, follow Zentiva’s LinkedIn profile, where we will be sharing highlights, team introductions, and booth activities in the lead-up to and during the event.  If you would like to connect with us on-site, simply scan the QR code below to get in touch or feel free to stop by our booth at Hall 3.0 – Stand 3.0G20. We look forward to welcoming you at CPHI Frankfurt and to shaping the future of healthcare together.

Zentiva at CPHI Frankfurt 2025

2025-09-15-Zentiva-at-CPHI

Innovation, Growth and Trusted Partnerships

Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to successfully transform the business, whilst investing to expand Zentiva’s portfolio of medicines and manufacturing footprint, both organically and through targeted M&amp;A. This transformation programme has built Zentiva into a highly successful standalone business, with a strong focus on operational excellence and R&amp;D capabilities, serving millions of patients across Europe. GTCR is a leading private equity firm with a long history of investments in the healthcare sector and deep domain expertise in the pharmaceutical industry specifically, having invested behind several leading platforms and completed dozens of acquisitions in the space in the last 20 years. With GTCR’s track record in the pharmaceutical space and its focus on partnering with management teams to build market-leading companies through organic growth, product innovation and strategic acquisitions, it is well-positioned to support Zentiva in this next phase of growth.  Tom Allen, Managing Director at Advent, said, “When we acquired Zentiva from Sanofi in 2018, we saw the opportunity to build an independent European leader in affordable medicines. By actively working with the management team and investing in the company’s capabilities, Zentiva has more than doubled its revenue and EBITDA, establishing a strong foundation for the future. Zentiva exemplifies Advent’s ability to carve out and transform non-core divisions into thriving, market-leading businesses. We are proud of what has been achieved and confident Zentiva will continue to excel under GTCR’s ownership.”Sean Cunningham, Managing Director and Head of Healthcare at GTCR, said, “We are delighted to partner with Steffen Saltofte and the talented Zentiva management team for its next phase of growth. The Company has an impressive track record of organic and inorganic expansion, a strong pipeline, and a highly efficient manufacturing platform, with a critical focus on delivering high-value medicines to patients across Europe. We look forward to supporting Zentiva as it continues to deliver on its mission.”The transaction is subject to customary regulatory approvals and its closing is expected to take place in early 2026.Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors and Freshfields as lead legal advisor.GTCR was advised by Barclays Bank PLC, acting through its Investment Bank, and BNP Paribas as lead financial advisors, Morgan Stanley &amp; Co. LLC as a financial advisor, and Kirkland &amp; Ellis LLP as legal advisor.  Media contacts:

Zentiva announces sale from Advent to GTCR

2025-09-11-Zentiva-announces-sale-from-Advent-to-GTCR

Episode #14 the Forest CreatorsIn conversation with Tomas Pala, Corporate Affairs Manager at Zentiva, Dr Nair recounts his journey from witnessing the devastating effects of deforestation to founding Forest Creators, a nonprofit organization that has planted over 3.3 million trees and established 128 Miyawaki forests, including the largest of its kind globally.Key Themes Explored in the Episode:The critical importance of biodiversity in building a resilient and sustainable futureInnovative approaches to forest creation in undeveloped and urban areasThe personal and emotional experiences that catalyzed a movementOpportunities for employee engagement and participation in Zentiva’s reforestation initiativesJust prior to recording, Dr Nair inaugurated a new forest project in Bangalore, planting 1,800 trees - a powerful example of the living change we strive to support and amplify through our sustainability efforts.This episode offers a compelling narrative of environmental leadership and community-driven impact. It invites listeners to reflect on their own role in fostering sustainability and to take part in Zentiva’s broader mission to protect and restore natural ecosystems. Stay tuned for upcoming episodes. In the meantime, spread the word by sharing this video to educate and empower as many individuals as possible. Additionally, discover how you can join the movement towards sustainability with our Sustainability Podcast.

Sustainability in Action

2025-08-20-Sustainability-Podcast

Dr RK Nair shares his vision for Reforestation in latest Zentiva Podcast

zentiva

daily

Header

Footer

Default

News

2022-07-08-allergy-day

World Allergy Day

Latest news

Zentiva at CPHI Frankfurt 2025

Zentiva announces sale from Advent to GTCR

Sustainability in Action

Explore

Stay tuned

Get in touch